MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-07-2026
Genmab A/S Total Non Current Liabilities 2011-2026 | GMAB
Annual Total Non Current Liabilities Genmab A/S
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 769 M | 158 M | 3.29 M | 3.63 M | - | 1.43 M | 178 M | 165 M | 126 M | 101 M |
All numbers in DKK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 769 M | 1.43 M | 167 M |
Quarterly Total Non Current Liabilities Genmab A/S
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 3.81 B | 3.29 B | 1.2 B | 1.23 B | - | - | 1.05 B | - | 863 M | - | 880 M | - | 769 M | - | 803 M | - | 158 M | - | 166 M | - | 3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in DKK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.81 B | 3 M | 1.18 B |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
79.1 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
158 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
34.7 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
7.32 M | - | 0.74 % | $ 768 M |  Israel |
 |
Galera Therapeutics
GRTX
|
64 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
645 K | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
355 M | $ 3.14 | 0.16 % | $ 653 M | USA |
 |
Eton Pharmaceuticals
ETON
|
4.56 M | $ 34.42 | 4.65 % | $ 926 M | USA |
|
Forte Biosciences
FBRX
|
10.5 M | $ 20.35 | 1.4 % | $ 263 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
4.97 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
30.4 M | $ 6.84 | 2.17 % | $ 187 M | Israel |
 |
Grifols, S.A.
GRFS
|
10.6 B | $ 8.21 | 4.72 % | $ 5.58 B |  Spain |
 |
Generation Bio Co.
GBIO
|
132 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
8.95 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
622 M | $ 90.48 | 3.06 % | $ 21.9 B | Germany |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.64 | 0.61 % | $ 436 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
497 K | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
14.6 M | $ 0.85 | 0.57 % | $ 142 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.06 M | - | -4.36 % | $ 27 M | USA |
 |
Compugen Ltd.
CGEN
|
31.3 M | $ 2.74 | 0.18 % | $ 256 M | Israel |
 |
Anika Therapeutics
ANIK
|
26.1 M | $ 15.15 | 2.23 % | $ 217 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
14 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.39 | 4.17 % | $ 5.58 M | Israel |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
189 M | $ 1.52 | 2.7 % | $ 178 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 20.45 | 4.9 % | $ 2.6 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |